Tafinlar/Mekinist (dabrafenib/trametinib)
pCPA File Number:
21500
Negotiation Status:
Concluded without agreement
Indication(s):
Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in patients who have not received any prior anti-cancer therapy for metastatic disease
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0226-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: